

Metallic DES: Tomorrow's Technology **From Proof of Concept to Clinical Evidence,** **Bioabsorbable Polymer Technology is** **Preferred to Durable Polymer**

Washington DC, Mon. 15th Sept. 2014



Robert A. Byrne, MB BCh PhD

Deutsches Herzzentrum, Technische Universität, Munich,
Germany




Disclosure Statement of Financial Interest

Robert A. Byrne, MB BCh PhD





Speakers fees:

Biotronik, B. Braun Melsungen AG

Delayed Arterial Healing After G1 DES




Durable Polymer Associated Inflammation




Inflammatory response to durable polymer coatings plays a central role in DAH

Overview of current stent designs

Strut and coating thickness in perspective





ISAR-TEST 4: Late Lumen Loss to 2 Years




Neoatherosclerosis within the EES

49M, EES
within the PES
in mid LAD





* Stent strut

OCT




IVUS




Polymer Coatings and Arterial Healing

- Most clinically effective durable polymer DES coatings contain **methacrylate polymer** e.g. PBMA (Cypher SES, Xience EES, Resolute ZES)*



- PBMA degrades to the monomer **methacrylic acid** which has proven cellular toxic effects#



Bioabsorbable polymer DES

Proof-of-concept chain of investigation

*Preclinical
studies*


*Human
imaging
trials*

*RCTs
Early FU*


*RCTs
Late FU*

Reduced inflammatory reaction with permanent polymers in porcine model

180 days



Histopathology and Morphometry @180 days (Porcine Model)



Bioabsorbable polymer DES

Proof-of-concept chain of investigation

*Preclinical
studies*

*Human
imaging
trials*

*RCTs
Early FU*


*RCTs
Late FU*

ISAR-TEST 6 OCT



Nobori BES vs. **Xience EES**

OCT at 6-8 m; n = 39



BP-BES



PP-EES




ISAR-TEST 6 OCT: Peri-stent Low Intensity Area (PLIA)




Improved Vasomotor Function with BP DES

Proximal Segment



Distal Segment



Bioabsorbable polymer DES

Proof-of-concept chain of investigation


*Preclinical
studies*

*Human
imaging
trials*


*RCTs
Early FU*

*RCTs
Late FU*

LEADERS




Cardiac death, MI, Reintervention




ISAR-TEST 4: Primary Endpoint at 1 Year

Cardiac death or TV-related MI or TLR -

MACE



$P_{\text{noninferiority BP-DES vs. PP-DES}} = 0.005$




COMPARE II and NEXT


Nobori
(BP Biolimus)

Xience
(PP Everolimus)

Cardiac death, MI, Reintervention




Reintervention (TLR)




ISAR-TEST 4: Primary Endpoint at 1 Year

Survival free of cardiac death, MI related to target vessel or TLR (%)



ISAR-TEST 4: Stent thrombosis at 1 Year

Definite or probable stent thrombosis (%)



BP-DES	1299	1256	1243	1236	1221	1213	1199
PP-DES	1304	1254	1240	1225	1204	1193	1189

Bioabsorbable polymer DES


Proof-of-concept chain of investigation


*Preclinical
studies*


*Human
imaging
trials*


*RCTs
Early FU*

*RCTs
Late FU*









Limitations of data

...cause for concern?

Bioabsorbable Polymer vs. Durable Polymer DES



CLINICAL RESEARCH

Interventional Cardiology

Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents


Evidence From a Comprehensive Network Meta-Analysis

Tullio Palmerini, MD,^a Giuseppe Biondi-Zoccai, MD,[†] Diego Della Riva, MD,^a Andrea Mariani, MD,^a Manel Sabaté, MD,[‡] Pieter C. Smits, MD,[§] Christoph Kaiser, MD,^{||} Fabrizio D'Ascenzo, MD,[¶] Giacomo Frati, MD,^{‡#} Massimo Mancone, MD,[‡] Philippe Genereux, MD,^{**||} Gregg W. Stone, MD^{***}
Bologna, Latina, Turin, and Pozzilli, Italy; Barcelona, Spain; Rotterdam, the Netherlands; Basel, Switzerland; New York, New York; and Montreal, Quebec, Canada



Network Meta-Analysis...

*Fun to
look at...*



Network Meta-Analysis...

*Fun to
look at...*




*...but
interpret
with
caution!*


Bioabsorbable Polymer vs. Durable Polymer DES

Stent Thrombosis: Trials with direct comparison vs. EES

ISAR-TEST 4



COMPARE II



NEXT

Definite stent thrombosis				
All patients	5 (0.31)	3 (0.19)	1.67 (0.41-8.14)	.48
Acute (0-1 d)	0	1 (0.06)		
Subacute (2-30 d)	2 (0.12)	0		
Late (31-365 d)	2 (0.12)	0		
Very late (>365 d)	1 (0.07)	2 (0.13)		
Stent thrombosis				
Possible	22 (1.4)	18 (1.1)	1.22 (0.66-2.31)	.53
Definite or probable	5 (0.31)	3 (0.19)	1.67 (0.41-8.14)	.48
Definite, probable, or possible	27 (1.7)	21 (1.3)	1.29 (0.73-2.30)	.38

Bioabsorbable Polymer vs. Durable Polymer DES



CLINICAL RESEARCH

Interventional Cardiology

Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents

Evidence From a Comprehensive Network Meta-Analysis

Tullio Palmerini, MD,^a Giuseppe Biondi-Zoccai, MD,[†] Diego Della Riva, MD,^a Andrea Mariani, MD,^a Manel Sabaté, MD,[‡] Pieter C. Smits, MD,[§] Christoph Kaiser, MD,^{||} Fabrizio D'Ascenzo, MD,[¶] Giacomo Frati, MD,^{‡#} Massimo Mancone, MD,[‡] Philippe Genereux, MD,^{**||} Gregg W. Stone, MD^{***}
Bologna, Latina, Turin, and Pozzilli, Italy; Barcelona, Spain; Rotterdam, the Netherlands; Basel, Switzerland; New York, New York; and Montreal, Quebec, Canada



Limitations of data

...not all BP-DES are equal

Stent Design & Thrombogenicity

Kolandaivelu et al Circulation 2011

STRUT CROSS-SECTIONS

DES





BMS



Thinner struts reduce acute phase stent thrombogenicity


POOLED

THICKNESS



Overview of current stent designs

Strut and coating thickness in perspective



Overview of current stent designs

Strut and coating thickness in perspective

New Generation Durable Polymer Coated Stent		Bioabsorbable Polymer Coated Stent				Bioabsorbable Scaffold
---	--	------------------------------------	--	--	--	------------------------

Abbott/Boston

Medtronic

Terumo

Translumina

Boston

BIOTRONIK

Xience/Promus

Resolute

Ultimaster

Yukon Choice PC

Synergy

Orsiro

CoCr/PtCr-EES



CoNi-ZES

CoCr-SES

316L-SES

PtCr-EES

CoCr-SES



Strut thickness


81 μm	91 μm		80 μm	87 μm	74 μm	60 μm	
------------------------------------	------------------------------------	--	------------------------------------	------------------------------------	------------------------------------	------------------------------------	--

Polymer coating

Circumferential 7-8 $\mu\text{m}/\text{side}$	Circumferential 6 $\mu\text{m}/\text{side}$		Abluminal 15 μm	Abluminal 5 μm	Abluminal 4 μm	Circumferential 4-7 $\mu\text{m}/\text{side}$	
--	--	--	-------------------------------	------------------------------	------------------------------	--	--


ISAR-TEST 4: Final 5-Year Data

Study Design




ISAR-TEST 4: Final 5-Year Data

Cardiac death/target vessel MI/TLR




ISAR-TEST 4: Final 5-Year Data

Target lesion revascularization




ISAR-TEST 4: Final 5-Year Data

Cardiac death/target vessel MI



ISAR-TEST 4: Final 5-Year Data

Definite/probable stent thrombosis



Perspective

...outcomes beyond 5-years remain unclear but all other things being equal I would prefer a stent without polymer!

Metallic DES: Tomorrow's Technology **From Proof of Concept to Clinical Evidence,** **Bioabsorbable Polymer Technology is** **Preferred to Durable Polymers**

Washington DC, Mon. 15th Sept. 2014



Robert A. Byrne, MB BCh PhD

Deutsches Herzzentrum, Technische Universität, Munich,
Germany

Metallic DES: Tomorrow's Technology **From Proof of Concept to Clinical Evidence,** **Bioabsorbable Polymer Technology is** **Preferred to Durable Polymers**

Washington DC, Mon. 15th Sept. 2014



Reserve Slides